Roche Wants EU Pharma Legislative Revision To ‘Dare Something New’
Executive Summary
New, more flexible regulatory approaches will be needed to deal with the integrated therapies coming through company pipelines, and the European Medicines Agency should play a “key orchestrating role” in smoothing the way, says Sabine Atzor, Roche’s head of EU regulatory policies.
You may also be interested in...
‘Regulatory Sandbox’ In EU's Sights For Innovative Drug Development & Approval
The European Commission’s vision for a more agile and streamlined drug development and assessment framework includes the use of controlled regulatory environments for testing innovative new drugs and technologies.
Regulators Back More Reliance On GMP Inspection Results
As medicines agencies increasingly turn to worksharing and other mechanisms to reduce duplication of effort, the Access Consortium has thrown its weight behind the use of reliance processes for national good manufacturing practice inspection outcomes.
Why Convergence & Reliance Are Key To Managing The Challenges Of CMC Post-Approval Changes
Implementing post-approval changes (PACs) is a challenging business. Different countries have their own PAC requirements, approval times and classification systems, which can potentially cause or exacerbate drug supply shortages. In this article, a group of pharmaceutical experts led by Andrew Deavin of GSK tells the Pink Sheet about the concrete progress that is being made to address these problems.